Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone
- PMID: 35975917
- PMCID: PMC10044490
- DOI: 10.1080/10826084.2022.2112230
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone
Abstract
Background and Objectives: Better understanding of predictors of opioid abstinence among patients with opioid use disorder (OUD) may help to inform interventions and personalize treatment plans. This analysis examined patient characteristics associated with opioid abstinence in the X:BOT (Extended-Release Naltrexone versus Buprenorphine for Opioid Treatment) trial. Methods: This post-hoc analysis examined factors associated with past-month opioid abstinence at the 36-week follow-up visit among participants in the X:BOT study. 428 participants (75% of original sample) attended the visit at 36 weeks. Logistic regression models were used to estimate the probability of opioid abstinence across various baseline sociodemographics, clinical characteristics, and treatment variables. Results: Of the 428 participants, 143 (33%) reported abstinence from non-prescribed opioids at the 36-week follow-up. Participants were more likely to be opioid abstinent if randomized to XR-NTX (compared to BUP-NX), were on XR-NTX at week 36 (compared to those off OUD pharmacotherapy), successfully inducted onto either study medication, had longer time on study medication, reported a greater number of abstinent weeks, or had longer time to relapse during the 24-week treatment trial. Participants were less likely to be abstinent if Hispanic, had a severe baseline Hamilton Depression Rating (HAM-D) score, or had baseline sedative use. Conclusions: A substantial proportion of participants was available at follow-up (75%), was on OUD pharmacotherapy (53%), and reported past-month opioid abstinence (33%) at 36 weeks. A minority of patients off medication for OUD reported abstinence and additional research is needed exploring patient characteristics that may be associated with successful treatment outcomes.
Keywords: Opioid abstinence; buprenorphine; extended-release injectable naltrexone; opioid use disorder.
Figures

Similar articles
-
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.J Subst Abuse Treat. 2021 Dec;131:108447. doi: 10.1016/j.jsat.2021.108447. Epub 2021 Apr 30. J Subst Abuse Treat. 2021. PMID: 34098301 Free PMC article. Clinical Trial.
-
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
-
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.Drug Alcohol Depend. 2021 Feb 1;219:108422. doi: 10.1016/j.drugalcdep.2020.108422. Epub 2020 Dec 9. Drug Alcohol Depend. 2021. PMID: 33352487 Free PMC article. Clinical Trial.
-
Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24. Addiction. 2018. PMID: 29396985 Free PMC article.
-
Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.Addiction. 2020 Aug;115(8):1413-1425. doi: 10.1111/add.14946. Epub 2020 Jan 17. Addiction. 2020. PMID: 31863669
Cited by
-
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder.Psychiatr Serv. 2023 Dec 1;74(12):1227-1233. doi: 10.1176/appi.ps.20220549. Epub 2023 Jun 20. Psychiatr Serv. 2023. PMID: 37337675 Free PMC article.
References
-
- Ahmad F, Rossen L, & Sutton P (2020). Provisional Drug Overdose Death Counts. CDC National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
-
- American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). American Psychiatric Association. 10.1176/appi.books.9780890425596 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous